Chardan initiated coverage of Clearside Biomedical with a Buy rating and $6 price target. The company’s CLS-AX program utilizes its proprietary microinjector to deliver axitinib suspension, a pan-VEGF receptor inhibitor, to a suprachoroidal space, with a potential to significantly decrease anti-VEGF treatment burden for patients with wet age-related macular degeneration, the analyst tells investors in a research note. The firm believes Clearside’s SCS delivery platform offers the potential for partnerships and internal pipeline expansion opportunities.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLSD:
- Clearside Biomedical reports Q2 EPS (10c), consensus (13c)
- Clearside Biomedical Announces Second Quarter 2024 Financial Results and Provides Corporate Update
- Options Volatility and Implied Earnings Moves Today, August 12, 2024
- CLSD Upcoming Earnings Report: What to Expect?
- Clearside Biomedical to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference